title: Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension.
abstract: OBJECTIVE
  It has been suggested that beta-blockers might be harmful in pulmonary arterial hypertension. However, no study has evaluated the effect of beta-blockers in these patients. The aim of this study was to investigate the effect of beta-blockers on exercise capacity and pulmonary hemodynamics in patients with portopulmonary hypertension receiving beta-blockers for the prophylaxis of variceal bleeding.
  
  
  METHODS
  Ten consecutive patients with moderate to severe portopulmonary hypertension (mean pulmonary artery pressure of 52 [10] mm Hg) underwent a 6-minute walk test and a right heart catheterization at baseline and 2 (1) months after beta-blocker withdrawal.
  
  
  RESULTS
  Following beta-blocker withdrawal, 9 of 10 patients increased their 6-minute walked distance with a mean increase in the whole group of 79 (78) meters (P = .01). Cardiac output increased by 28% (P < .01) with no change in mean pulmonary artery pressure, resulting in a 19% decrease in pulmonary vascular resistance (P < .01). Increases in cardiac output were related to a 25% increase in heart rate (P < .01), whereas stroke volume was unchanged (P = .65). The improvements in exercise tolerance were associated with increases in chronotropic response (maximal heart rate minus resting heart rate) from 18 (9) to 34 (12) beats/min (P < .01) during the 6-minute walk test.
  
  
  CONCLUSIONS
  In patients with moderate to severe portopulmonary hypertension, beta-blockers are associated with significant worsening in exercise capacity and pulmonary hemodynamics. These deleterious effects support the contraindication of beta-blockers in patients with portopulmonary hypertension.
authors.affiliation: Centre des Maladies Vasculaires Pulmonaires (UPRES EA 2705), Service de Pneumologie, Hôpital Antoine Béclère, Clamart, France. steeveprovencher@hotmail.com
authors.forename: Steeve
authors.initials: S
authors.lastname: Provencher
authors.forename: Philippe
authors.initials: P
authors.lastname: Herve
authors.forename: Xavier
authors.initials: X
authors.lastname: Jais
authors.forename: Didier
authors.initials: D
authors.lastname: Lebrec
authors.forename: Marc
authors.initials: M
authors.lastname: Humbert
authors.forename: Gerald
authors.initials: G
authors.lastname: Simonneau
authors.forename: Olivier
authors.initials: O
authors.lastname: Sitbon
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D002302:Cardiac Output / Q000187:drug effects; D056486:Chemical and Drug Induced Liver Injury; D015444:Exercise / Q000502:physiology*; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006975:Hypertension, Portal / Q000188:drug therapy*; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010809:Physical Fitness; D016138:Walking / Q000502:physiology
chemical_list: D000319:Adrenergic beta-Antagonists